Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase III Study of PXL-01 for Prevention of Postsurgical Adhesions after Tendon and Nerve Repairs in the Hand

Next Previous
X
Search
Trial Profile

A Phase III Study of PXL-01 for Prevention of Postsurgical Adhesions after Tendon and Nerve Repairs in the Hand

Status: Planning
Phase of Trial: Phase III

Latest Information Update: 06 Feb 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ensereptide (Primary)
  • Indications Post-surgical adhesions
  • Focus Registrational; Therapeutic Use
  • Sponsors ProMore Pharma

    • Most Recent Events

    • 01 Feb 2019 According to a ProMore Pharma media release, the company is working towards the goal of being able to start our clinical study no later than the first half of 2020.
    • 01 Feb 2019 According to a ProMore Pharma media release, due to number of manufacturing issues of investigational drug the company is fixing the manufacturing chain. The company plans to increase number of clinics (including hospitals in Italy) to reduce the likelihood of time loss.
    • 19 Nov 2018 According to a ProMore Pharma media release, the company has received approval from the Drug Controller General of India to initiate this trial.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top